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Abstract
In the present study, a new strategy to link AZT with betulin/betulinic acid (BA) by click
chemistry was designed and achieved. This conjugation via a triazole linkage offers a new
direction for modification of anti-HIV triterpenes. Click chemistry provides an easy and
productive way for linking two molecules, even when one of them is a large natural product.
Among the newly synthesized conjugates, compounds 15 and 16 showed potent anti-HIV activity
with EC50 values of 0.067 and 0.10 µM, respectively, which are comparable to that of AZT (EC50:
0.10 µM) in the same assay.
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Due to the expanded and improved HIV programs, the number of new global HIV infections
declined 19% over the past decade. However, this progress is fragile and unevenly
distributed. HIV incidence is still increasing in some countries and regions, and too many
new infections are occurring, 2.6 million in 2009 alone, contributing to the current global
incidence of 33.3 million.1 New infections continue to outpace the number of people placed
on treatment, and the efficacy of the treatments is hampered by the emergence of drug-
resistant viral strains and severe drug-drug interactions. Therefore, novel potent
antiretroviral agents with different targets and acceptable prices are still urgently needed.
Two lupine-type triterpenes betulin and betulinic acid (BA), which are readily available
from the birch tree in large quantity, exhibit diverse pharmacological activities, including
anti-HIV, anti-cancer, and anti-inflammatory activities.2 Among the BA/betulin derivatives,
bevirimat [3-O-(3′,3′-dimethylsuccinyl)betulinic acid, 14] was found to exhibit remarkable
anti-HIV-1 activity against primary and drug-resistant HIV-1 isolates,3, 4 representing a
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unique first in a class of anti-HIV compounds termed maturation inhibitors (MIs).4, 5
Bevirimat has recently succeeded in Phase IIb clinical trials.6–9
In our prior study, AZT (3′-azido-3′-deoxythymidine), a clinically used nucleoside reverse
transcriptase inhibitor (NRTI), was conjugated with 3-O-(3′,3′-dimethylsuccinyl)betulin at
its C-28 position using different linkers. The goal was to provide multi-target therapeutics in
one molecule in order to reduce the risk of drug-drug interaction, which can occur from
mixing monotherapies,.10 The conjugates were formed via an ester bond, which was meant
to subsequently be hydrolyzed inside the cells and release two different chemical entities
exerting two pharmacological functions, anti-maturation and anti-reverse transcriptase.
However, one potential drawback of this design is that the hydroxyl group of AZT, which
needs to undergo phosphorylation inside host cells to become active, forms the linker bond
with the betulin derivatives. Consequently, the inhibitory ability of AZT is highly dependent
on the ability of the conjugate to dissociate. In order to improve this issue, we investigated
another strategy to link AZT with betulin and BA via the azido group of AZT by using click
chemistry.
Click chemistry as introduced by K. Barry Sharpless is a chemical philosophy to mimic
nature’s ability to make carbon-heteroatom bonds rather than carbon-carbon bonds.11
Conjugation of AZT with betulin and BA by this methodology has the following potential
benefits. 1) Click chemistry is designed to link the azido group of AZT with an alkyne group
on betulin/BA derivatives, leaving the hydroxyl group of AZT free to be phosphorylated. 2)
The linking triazole group is physiologically stable in cells. Thus, the new conjugated
molecule will not be degraded inside the cells, which should reduce the potential drug-drug
interactions. 3) In addition, the triazole linkage formed by click chemistry may also offer
extra interaction with virus proteins. Based on this rationale, the present study reports the
synthesis and anti-HIV activity of the newly designed AZT-betulin and AZT-BA
conjugates.
The synthetic route to compounds conjugated at the C-3 position of betulin is outlined in
Scheme 1. The C-28 hydroxyl of betulin was first protected by reaction with tert-
butyldimethylsilyl chloride (TBSCl) to yield the silyl ether 1. Prop-2-ynyl groups were then
introduced at the C-3 position as either an ether (2) or carbonate ester (3). Compounds 2 and
3 were then reacted with the azido group of AZT in the presence of Cu and CuSO4·5H2O to
furnish final compounds 8 and 9 in quantitative yields. Analogous final compounds 10 and
11 were obtained by the same click reaction of AZT with the C-28 de-protected betulin
derivatives 4 and 5. Oxidation of the C-28 hydroxyl of 4 with Jones reagent yielded 6, which
was also reacted with AZT to yield 12, an AZT-BA conjugate. Finally, a 3′,3′-
dimethylsuccinyl ester was introduced at the C-28 position of 4 to yield compound 7, which
was converted by click chemistry to the conjugate 13. Scheme 2 depicts the synthesis of
AZT-bevirimat conjugates. A prop-2-ynyl ester moiety was added to the C-28 position of
bevirimat (14) to furnish 15, followed by click reaction of 15 with AZT to yield final
compound 16. Compared with the previous yields (42.7–87.3%) for conjugating AZT with
betulin derivatives via an ester bond,10 the click reactions of AZT with betulin/BA
derivatives were achieved quantitatively, which is a significant advantage in the last step of
synthesizing the target compounds. In addition, the reaction time was shortened significantly
to 30 min by using microwave conditions at 120 °C (followed by dilution with EtOAc,
washing with NaHCO3 and brine, and chromatography), rather than the prior overnight
esterification reaction. Therefore, the click reaction provides a much more productive and
rapid approach to obtain the final products of AZT-betulin/BA conjugates.
The anti-HIV activity data of all new compounds are summarized in Table 1. Among the
tested compounds, conjugates 8 and 13 with AZT linked through the C-3 side chain of
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betulin/BA showed moderate antiviral activity with EC50 values of 0.19 and 0.35 µM,
respectively. The C-3 ether bond (8) was favored for activity compared with the C-3
carbonate ester bond (corresponding conjugate 9 was inactive). Conjugates with a free C-28
hydroxyl (10 and 11) or carboxylic acid group (12) showed no inhibitory activity, compared
with conjugates with a C-28 TBS ether (8) or dimethylsuccinyl ester (13). Between the two
active conjugates, the smaller C-28 TBS side chain in 8 was favored compared with the
longer dimethylsuccinyl side chain in 13. Overall, in this limited data set, when AZT and
betulin/BA are conjugated at the C-3 position, a shorter distance between AZT-betulin/BA
and the presence of a small extra side chain at C-28 are important for the conjugates’
antiviral activity.
The non-conjugated 15 with a 3-O-3′,3′-dimethylsuccinyl side chain at C-3 and propynyl
ester moiety at C-28 showed potent anti-HIV activity with an EC50 of 0.067 µM and a
selectivity index (SI, ratio of cytotoxic/anti-viral activity) of 226. The AZT-bevirimat
conjugate 16 also exhibited anti-HIV activity with an EC50 of 0.10 µM and a SI of 101.
Thus, these two compounds and AZT (EC50: 0.10 µM) showed comparable activity in our
assay system. As a pioneer compound, conjugate 16 demonstrates that a click reaction can
be used easily with a large natural product (e.g. BA), which contains a terminal alkyne
moiety, to form conjugates. The potent anti-HIV activity of compounds 15 and 16 proves
that the incorporation of a C-28 side chain in bevirimat may result in retained or even
increased antiviral activity. We are currently investigating synthesis and antiviral evaluation
of additional AZT-bevirimat conjugates with different sizes/lengths of linkers between the
C-28 carboxylic acid and the triazole moiety formed by click reaction with AZT.
In conclusion, conjugation via triazole linkage offers a new direction of modification of anti-
HIV triterpenes. Click chemistry provides an easy and productive way for linking two
molecules, even when one of them is a large natural product. Preliminary results indicated
that AZT-betulin/BA conjugates with proper substitutions at the C-3 and C-28 positions
showed potent antiviral activity comparable to bevirimat and AZT. Mechanistic studies are
currently ongoing.
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Scheme 1. AZT conjugation at C-3 position
Reagents and conditions: (a) TBSCl, DMF/THF (1:1), DMAP, DIPEA, 0 °C; (b) propargyl
bromide, NaH, THF; (c) triphosgene, pyridine, THF,12 and then propargyl alcohol, pyridine,
THF; (d) TBAF, THF; (e) Jones reagent, acetone; (f) 2,2-dimethylsuccinic anhydride,
DMAP, DMF, 70 °C; (g) AZT, Cu, CuSO4•5H2O, H2O, t-BuOH, under N2.13, 14
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Scheme 2. AZT conjugation at C-28 position
Reagents and conditions: (a) 2,2-dimethyl-succinic anhydride, DMAP, DMF, 70 °C; (b)
propargyl bromide, Cs2CO3, DMF/THF (1:1), room temperature; (c) AZT, Cu,
CuSO2•5H2O, H2O, t-BuOH, under N2.
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Table 1
Anti-HIV data against HIV-1NL4–3 infected MT-4 cells.
Compound EC50 (µM) CC50 (µM) SI a
2 -b - -
3 - - -
4 - - -
5 - - -
6 - - -
7 - - -
8 0.19 > 4.6 > 24
9 - - -
10 - - -
11 - - -
12 - - -
13 0.35 > 4.6 > 13
15 0.067 15.3 226
16 0.10 11.2 101
Bevirimat (14) 0.077 13.2 171
AZT 0.10 140 1385
a
Selectivity index = CC50/EC50 (CC50, the concentration of test sample that was cytotoxic to 50% of the mock-infected cells; EC50, the
concentration of the test sample that was effective to suppress HIV replication by 50%)
b
No activity
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